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ABSTRACT
Current methods for measuring deoxyribonucleoside
triphosphates (dNTPs) employ reagent and labor-
intensive assays utilizing radioisotopes in DNA
polymerase-based assays and/or chromatography-
based approaches. We have developed a rapid and
sensitive 96-well fluorescence-based assay to quan-
tify cellular dNTPs utilizing a standard real-time PCR
thermocycler. This assay relies on the principle that
incorporation of a limiting dNTP is required for
primer-extension and Taq polymerase-mediated
5–30 exonuclease hydrolysis of a dual-quenched
fluorophore-labeled probe resulting in fluorescence.
The concentration of limiting dNTP is directly pro-
portional to the fluorescence generated. The assay
demonstrated excellent linearity (R
2>0.99) and can
be modified to detect between  0.5 and 100pmol of
dNTP. The limits of detection (LOD) and quantifica-
tion (LOQ) for all dNTPs were defined as <0.77 and
<1.3pmol, respectively. The intra-assay and inter-
assay variation coefficients were determined to be
<4.6% and <10%, respectively with an accuracy of
100±15% for all dNTPs. The assay quantified intra-
cellular dNTPs with similar results obtained from a
validated LC–MS/MS approach and successfully
measured quantitative differences in dNTP pools in
human cancer cells treated with inhibitors of thymi-
dylate metabolism. This assay has important appli-
cation in research that investigates the influence of
pathological conditions or pharmacological agents
on dNTP biosynthesis and regulation.
INTRODUCTION
The coordinated regulation of intracellular deoxyribo-
nucleoside triphosphates (dNTP) pools is critical for the
ﬁdelity of DNA synthesis during DNA replication and
repair in both prokaryotic and eukaryotic organisms (1).
Dysregulation of intracellular dNTP pools is observed in a
large number of pathological conditions and represents a
critical mechanism of action of a number of pharmaco-
logical inhibitors. The quantiﬁcation of cellular dNTP
levels is therefore of fundamental importance in assisting
our understanding of the mechanisms of action of
pharmacological agents and the biology of physiological
and pathological phenomena that result in altered dNTP
biosynthesis.
One evolving and potentially impactful application of
ﬂuorescence-based technology is the detection and quan-
tiﬁcation of dNTPs. dNTPs in extracts from cultured cells
are frequently quantiﬁed by two independent methods; a
DNA polymerase-based assay based upon the enzymatic
synthesis of DNA and a high-performance liquid chroma-
tography (HPLC)-based assay. Although protocols that
employ radioisotopes in polymerase-based assays for
dNTP detection are sensitive and quantitative and have
undergone continued optimization, such methods can
employ hazardous reagents in cellular extraction protocols
and necessitate the use of radioactivity in the form of
tritium-labeled dNTPs, with some protocols also requiring
32P-labeled primers. Such reagents can pose health
hazards and require specialized handling, dedicated equip-
ment, storage and disposal and often necessitate safety
inspections in line with government and institutional regu-
lations (2–7). DNA polymerase-based assays represent an
indirect method for quantifying dNTPs and as such
various aspects of the assay from the point of cellular
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assay conditions can inﬂuence the validity and robustness
of the results. In addition DNA polymerase-based assays
are also hampered by potential interference from ribonu-
cleotides (rNTPs) and the utilization of different DNA
polymerases was recently proposed for the detection
of the different canonical dNTPs to circumvent this (7).
Therefore, DNA polymerase-based assays require rigorous
testing and optimization prior to use to ensure tangible
and reproducible results.
The continued development of techniques such as
HPLC and HPLC coupled with mass spectrometry (MS)
have solved some of these issues and these assays represent
a more direct analytical method of quantifying dNTPs
(8–11). However, despite being precise and reproducible,
these procedures are not as sensitive as radioisotope-based
DNA polymerase assays and require larger sample sizes.
In addition, these techniques are time, reagent and labor-
intensive and require costly instrumentation and skilled
operators which limits the overall utility of this procedure
in conventional laboratories. In addition, both HPLC-
based and DNA-polymerase-based assays are somewhat
limited in their throughput capabilities in their current
respective forms.
In the current article, we describe the design and valid-
ation of a rapid, sensitive and reproducible 96-well
ﬂuorescence-based method for measuring dNTPs that
eliminates the need for radioactivity and is compatible
with a simple methanol-based cellular dNTP extraction
protocol. This assay eliminates the requirement for haz-
ardous reagents and specialized HPLC and MS-based in-
strumentation. The assay principle is similar to technology
found in a typical TaqMan PCR but utilizes a synthetic
oligonucleotide user-supplied template, a single primer
and a dual-quenched ﬂuorophore-labeled probe. A
number of templates with varying sensitivities and linear
capabilities for each dNTP were designed and validated
and could reproducibly detect between 0.3 and 100pmol
of corresponding dNTP depending on assay requirements
and conditions. The assay was validated according to
the US Food and Drug Administration ‘Analytical
Procedures and Methods Validation’ guidelines and
demonstrated excellent linearity (R
2>0.99) with excellent
accuracy, sensitivity, recovery and reproducibility. This
novel method showed good concordance to a validated
LC–MS/MS-based approach when performed in compari-
son. Finally, the assay was successfully applied to the
detection of dNTPs from human cancer cells.
MATERIALS AND METHODS
Chemicals, drugs and reagents
The oligonucelotide primer, templates and ﬂuorophore-
and quencher-labeled detection probes were synthesized
by Integrated DNA Technologies (Coralville, IA, USA),
subjected to polyacrylamide gel electrophoresis puriﬁca-
tion and reconstituted in Omnipur sterile nuclease-free
water (EMD Chemicals USA, Gibbstown, NJ, USA) at
a stock concentration of 100mmol/l. The two non-emissive
(dark) quenching molecules incorporated into the
detection probes include the Iowa black ﬂuorescein
quencher (IBFQ; absorption max=531nm) and ZEN
(non-abbreviation; absorption max 532nm). The ﬂuores-
cent label utilized was 6-FAM (50-carboxyﬂuorescein; ex-
citation max.=494nm, emission max.=520nm). Probes
were further diluted to a working stock of 10mmol/l and
aliquoted to avoid repeated freeze/thaw cycles. AmpliTaq
Gold DNA Polymerase, GeneAmp 10  PCR Buffer 2,
MgCl2 and MicroAmp Optical 96-well Reaction Plates
were purchased from Applied Biosystems (Carlsbad,
CA, USA) and were sealed with ThermalSeal RT2RR
sealing ﬁlm from Excel Scientiﬁc (Victorville, CA, USA).
dNTPs were purchased individually at stock concentra-
tions of 100mmol/l from New England Biolabs at
HPLC-certiﬁed >99% purity (Ipswich, MA, USA).
Ribonucleoside triphosphates (rNTPs) were purchased
individually from Applied Biosystems at stock concentra-
tions of 10mmol/l. Fluorodeoxyuridine (FUdR) and
5-ﬂuorouracil (5-FU) were obtained from Sigma
(St Louis, MO, USA) and maintained in sterile double-
distilled water and DMSO, respectively at stock concen-
trations of 50mmol/l. Pemetrexed disodium salt (>99%)
was purchased from LC Laboratories (Woburn, MA,
USA) and maintained in sterile double-distilled water at
a stock concentration of 50mmol/l. Recombinant
human deoxyuridine nucleotidohydrolase (dUTPase) was
expressed and puriﬁed as described previously (12).
Assay components, instrumentation and real-time
ﬂuorescence conditions
Reaction mixtures contained primer, probe and template
at an equimolar ﬁnal concentration of 0.4mmol/l. MgCl2
was included at a ﬁnal concentration of 2mmol/l. Non-
limiting dNTPs were included in the reaction mix in excess
at a ﬁnal concentration of 100mmol/l (the dNTP to be
assayed was excluded). AmpliTaq Gold DNA polymerase
was added at 0.875U/reaction, 2.5mlo f1 0   PCR Buffer 2
added and nuclease-free ddH20 added to a ﬁnal reaction
volume of 25ml. For analysis of cell extracts, the volume
of ddH20 was modiﬁed to accommodate the addition of
2.5ml of cell extract. For dUTP determination from cell
extracts, the volume of ddH20 was further modiﬁed to
accommodate an additional 1ml of dUTPase (10ng/ml).
Thermal proﬁling and ﬂuorescence detection was per-
formed using the ‘isothermal’ program on board an
Applied Biosystems 7500 Real-Time PCR System. For
analysis of dNTPs, the thermal proﬁle consisted of a
10min 95 C step to ‘hot-start’ the Taq polymerase and a
primer extension time of up to 30min at 60 C depending
on the application. Raw ﬂuorescence spectra for 6-FAM
was measured using ﬁlter A at speciﬁed time intervals
(typically every 5min) to follow assay progression using
Sequence Detection Software (SDS Version 1.4, Applied
Biosystems) and exported and analyzed in Microsoft Excel
(Microsoft, Redmond, WA, USA) and Prism 5.0
(GraphPad Software, La Jolla, CA, USA). In all cases,
ﬂuorescence values for blank reactions (limiting dNTP
omitted) were subtracted to give normalized ﬂuorescence
units (NFUs) to account for background probe
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found in Supplementary Figure S2.
Cell lines and cell culture conditions
The human colorectal cancer cell line HCT116 was
purchased from American Type Culture Collection
(Lockville, MD, USA). HCT116 cells were maintained
in McCoy’s 5A media (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (Lonza,
Walkersville, MD, USA) with penicillin/streptomycin,
sodium pyruvate and L-glutamine (Invitrogen). For
pemetrexed analyses, cells were incubated in folate-
depleted RPMI supplemented with 25nmol/l
5-Formyltetrahydrofolate, 10% fetal bovine serum
(Lonza), penicillin/streptomycin, sodium pyruvate and
L-glutamine for 24h prior to treatment. Cells were main-
tained in a humidiﬁed Forma incubator (Forma,
Waltham, MA, USA) at 37 C with 5% CO2 and routinely
screened for mycoplasma using the MycoALERT detec-
tion kit (Lonza) and veriﬁed mycoplasma negative.
Assay validation, data analysis and statistics
The dNTP detection assay described herein was rigorously
tested in accordance with the US Food and Drug
Administration ‘Analytical Procedures and Methods
Validation’ and ‘Bioanalytical Method Validation’ guide-
lines available at http://www.fda.gov. The relationship
between assay response and known concentrations of the
analytes (dNTPs) was analyzed by a 5-point (minimum)
calibration curve. Calibration curves were obtained by
assaying serial dilutions of dNTP standards diluted with
ultra-pure nuclease-free water to the desired concentration
and evaluated using regression coefﬁcients (R
2). Samples
were assayed in triplicate, and experiments were repeated
on three independent occasions as appropriate. The limit
of detection (LOD) was deﬁned as the mean value of the
negative blind controls plus 3 SDs of the mean, i.e. the
concentration with a signal:noise ratio of 3:1. The limit of
quantiﬁcation (LOQ) was deﬁned as the mean value of the
negative controls plus 5 SD determined from three inde-
pendent assays (signal:noise ratio of 5:1). Coefﬁcient of
variation (%CV) values were calculated from the cumula-
tive mean and SD of replicates. Inter-assay %CVs were
calculated from three independent experiments performed
on different days. The intra-assay %CV represents the
mean±SD %CV obtained from assaying replicate
samples within three identical yet independent assays per-
formed on the same day. The accuracy was assessed by
comparing the nominal dNTP concentrations with the
corresponding calculated values based on the calibration
curve and presented as a percentage. Recoveries were
determined by obtaining the result from a known quantity
of a dNTP standard spiked into an unknown extract and
comparing this to the sum of the individual results
obtained for the dNTP standard and the cell extract. All
dNTP quantities are expressed as picomoles or picomoles
per 10
6 cells as appropriate.
Extraction of intracellular dNTPs
Cells were plated in 10-cm tissue culture dishes (TPP,
Trasadingen, Switzerland) at 1 10
6 and allowed to
adhere and enter log-phase growth for 48h. Cells were
then treated with vehicle or FUdR (1mmol/l) for 4h
after which the medium was aspirated and cells were
rinsed with phosphate-buffered saline (PBS) to remove
residual media. The adherent cells were detached by
trypsin, resuspended gently in 10ml of ice-cold PBS and
and a 100ml aliquot removed to determine cell number
via haemocytometer. The samples were centrifuged for
5min at 3000g at 4 C, the supernatant discarded and
cell pellets were then resuspended in 500ml of ice-cold
60% methanol, vortexed vigorously to resuspend, placed
at 95 C for 3min and sonicated for 30s in a Branson
Soniﬁer 450 (Branson, Danbury, CT, USA). The
extracts were centrifuged (16000g for 5min at 4 C) to
remove cell debris, precipitated protein and DNA. The
resultant cell extract supernatants were passed through
pre-equilibrated Amicon Ultra-0.5-ml centrifugal ﬁlters
at 4 C to remove macromolecules >3kDa according to
the manufacturer’s directions (Millipore, Billerica, MA,
USA). The ﬁltrate was evaporated under centrifugal
vacuum at 70 C and the resultant pellet was resuspended
in 25ml nuclease-free water ready to assay or stored at
 80 C until use.
Liquid chromatography MS
A previously validated LC–MS/MS approach was utilized
to determine dNTP concentrations (13). Standard solu-
tions of dATP, dTTP, dCTP and dGTP at a concentration
of 100mmol/l were utilized to construct a 9-point calibra-
tion curve consisting of 0, 50, 75, 100, 250, 500, 750, 1000
and 2500ng/ml standards. Each standard was spiked with
100ml of a mixture of 500ng/ml dideoxyCTP (ddCTP),
1000ng/ml of dideoxyGTP (ddGTP), 500ng/ml of
2-chloroadenosine triphosphate (2-ClA) and 500ng/ml of
ADV-DP to serve as internal quality control standards.
Calibration standards were processed simultaneously.
Least-square linear regression using a weighting of 1/x
2
was performed to establish a linear calibration curve
between the area ratios of analyte to internal standard
and the concentrations of analyte. The linearity was estab-
lished by the back calculate concentration for each cali-
bration standard. The comparison of the actual
concentration to the expected theoretical value established
the precision and accuracy of the assay. Samples were
vacuum dried using an SPD SpeedVac and suspended in
0.5ml of 0.01% formic acid in HPLC H2O which con-
tained two units of acid phosphatase/ml (Sigma) and
incubated for 30min at 37 C, to dephosphorylate and
yield the corresponding deoxynucleoside. The dephos-
phorylated standards and quality controls were vacuum
dried in a SPD SpeedVac and reconstituted with 50mlo f
7% methanol in deionized water and 30ml of the sample
was injected into an Agilent 1100 (Agilent, San Jose, CA,
USA) high performance liquid chromatography (HPLC)
system running an ACE C18 column 2.0 50mm with
3mm packing (Advanced Chromatography Technologies;
Aberdeen, Scotland), coupled to an Sciex API 3000 triple
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Biosystems). The operating software was Analyst 1.4.2.
A step gradient program was applied to separate all the
analytes with a ﬂow rate of 300ml/min. The mobile phase
consisted of methanol as component A and 20mmol/l
ammonia acetate buffer at pH 4.5 as component B.
After separation, the analytes in the HPLC efferent were
introduced into the mass spectrometer through a
TurboIonspray interface coupled with a heated turbo
nitrogen stream to evaporate solvents and to increase ion-
ization efﬁciency. The mass spectrometer operated in
distinct periods: the ﬁrst period had 8-min scan time for
the detection of deoxycytidine (dC), dideoxycytidine
(ddC), deoxyguanosine (dG) and dT; the second period
lasted 9min and scanned for deoxyadenosine (dA),
dideoxyguanosine (ddG), and 2-ClA. The following mass
transitions were monitored—dA: 252!136, retention
time of 7min; dT: 243!127, retention time of 4min;
dG: 268!152, retention time of 3.5min; dC: 228!112,
retention time of 1.5min; ddC: 212!112, retention time
of 3min; ddG: 252!152, retention time of 7.5min; ADV:
274!162, retention time of 2min; 2-ClA: 302!170, re-
tention time of 11min.
RESULTS
Assay concept overview
The goal of the current study was to develop a rapid and
sensitive ﬂuorescence-based assay with throughput cap-
ability to detect and measure dNTPs as an alternative to
currently employed approaches that utilize radioisotope-
based DNA polymerase assays or HPLC and/or LC–MS/
MS methodology. The DNA polymerase-based assay
described previously by Sherman and Fyfe (4) was utilized
as a platform to develop a non-radioactive ﬂuorescence-
based assay to detect the limiting dNTP. The aforemen-
tioned studies relied upon the incorporation of a
radiolabeled nucleotide into a template–primer assay dur-
ing DNA polymerase-catalyzed enzymatic synthesis of
DNA. Upon depletion of the dNTP being measured, the
DNA polymerase stalls and the incorporation of
radiolabeled nucleotide ceases, resulting in extension
delay and/or chain termination. The amount of incorpor-
ation of the radiolabeled nucleotide at the completion of
the reaction is directly proportional to the concentration
of the limiting dNTP being assayed. We employed a
similar DNA polymerase-based approach utilizing a
modiﬁed oligonucleotide template with three distinct re-
gions: a 30 primer-binding region, a mid-template dNTP
detection region and a 50 6-FAM-labeled probe-binding
region. During the reaction, the probe and primer hybrid-
ize to the oligonucleotide template to form the tem-
plate:primer:probe complex (TPP complex). When Taq
polymerase binds to the primer in the TPP complex and
the dNTP to be measured is present, successful extension
of the nascent strand occurs and the inherent 50 to 30 exo-
nuclease activity of Taq polymerase cleaves and displaces
the 6-FAM-labeled probe in a 50 to 30 direction, releasing
the 6-FAM ﬂuorophore from its proximity to the two
quenchers. This displacement effectively disrupts the
Fo ¨ rster resonance energy transfer (FRET) and the result-
ing ﬂuorescence detected upon excitation is directly pro-
portional to the amount of the limiting dNTP available in
the assay for incorporation (Figure 1). Conversely, when
the limiting dNTP becomes exhausted and is no longer
available for incorporation, Taq polymerase stalls and ex-
tension delay and/or chain termination of the nascent
strand occurs. In this instance, probe hydrolysis/degrad-
ation does not occur and the probe remains dark as ﬂuor-
escence remains quenched via FRET.
Assay development and design considerations
One key advantage of the most recent modiﬁcations to the
radioisotope DNA polymerase-based assays was the high
signal:noise ratio that facilitates the detection of extremely
low picomole quantities of dNTP (0.1pmol) with great
accuracy. This is possible through the removal of unincor-
porated radioactivity via numerous wash steps prior
to scintillation counting, thus signiﬁcantly reducing back-
ground noise. The current assay utilizes an enclosed system
where the generated ﬂuorescence signal is detected in the
presence of any remaining intact ﬂuorophore-labeled
probe which, even in its intact and quenched state, will
demonstrate some residual background ﬂuorescence. The
goal therefore was to create a detection system that
remains as dark as possible in the absence of analyte-
generated signal and thus maintains a high signal:noise
ratio that will facilitate the detection of low picomole
quantities of dNTP required for most applications.
Probe design
A 23-bp oligonucleotide hybridization probe was designed
that incorporates two similar napthyl-azo structure-based
quenching molecules to maximize the signal:noise ratio.
The IBFQ quencher was incorporated at the 30-end of
the probe and an additional phosphoramidite internal
ZEN quencher was incorporated 9bp from the 50
6-FAM ﬂuorophore (Table 1). Dark quenchers that have
maximum absorption wavelengths in the 531–534nm
range such as IBFQ and ZEN and other functionally-
similar and commercially available dark quenchers
including black hole quencher 1 (BHQ-1, Sigma; absorp-
tion max: 534nm) and Eclipse (Glen Research, Sterling,
VA, USA; absorption max: 530nm) have demonstrated
efﬁcient FRET when coupled with ﬂuorescent dyes that
emit in the green to pink spectral range including the
6-FAM ﬂuorophore (14,15). The incorporation of two
quenching molecules also serves two purposes; two
quenchers will ensure maximal FRET to both quenchers
minimizing the quantum yield and background ﬂuores-
cence generated in the absence of Taq-mediated probe hy-
drolysis. In addition, the close proximity of the internal
ZEN quencher reduces the physical distance between the
reporter ﬂuorophore and the quencher to only 9bp which
is reportedly a key determinant that increases the efﬁ-
ciency of the FRET mechanism (16). Attempts to develop
the assay using an identical 23-bp single IBFQ-quenched
probe were unsuccessful and the incorporation of the ZEN
internal quencher was critical for the sensitivity in this
assay (data not shown). In addition, quenching in linear
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based probes such as FAM also occurs via the non-
FRET-based mechanism of static quenching which may
further limit assay background and improve signal:noise
ratio (17).
dNTP template and primer design
The ﬁrst oligonucleotide detection template (DT) designed
and evaluated for the detection of dTTP was dTTP-DT6
depicted in Figure 1. This template requires six dTTP nu-
cleotides to be available for incorporation into the nascent
strand as dTMP (each dTMP event is separated by two
dAMP incorporation events) by Taq polymerase before
the exonuclease activity of Taq cleaves the 6-FAM
ﬂuorophore resulting in ﬂuorescence. The requirement
for six near-sequential dTTP incorporations in the nascent
strand greatly limits the probability of ﬂuorescence
generated as a result of dNTP misincorporation by Taq
polymerase which reportedly can occur in the presence of
severely imbalanced dNTP concentrations (18). However,
the requirement for six dTTP molecules per probe
degradation-induced ﬂuorescence event also has the po-
tential to limit the sensitivity of the assay. To evaluate
this, two additional oligonucleotide DTs were designed
to test the sensitivity capabilities, one requiring two
dTTPs for incorporation (dTTP-DT2) and a template
requiring only a single dTTP for incorporation during pri-
mer extension to facilitate probe hydrolysis (dTTP-DT1).
Figure 1. Simpliﬁed schematic illustrating the principle mechanism involved in the ﬂuorescence-based assay for measuring dNTP concentrations.
Detection of dTTP using template DT6 is given as the example. The template is depicted in blue, the FAM-dTTP probe in green and primer NDP1
in red. Brieﬂy, as the temperature declines from the 95 C hot-start, the probe anneals to the template ﬁrst (65–70 C), followed by the primer at 60 C
to form the TPP complex at which point Taq polymerase begins extension of the nascent strand. In the presence of a sufﬁcient concentration of
limiting dNTP (six dTTP molecules in the example of dTTP-DT6), successful primer extension occurs through the mid-template dNTP detection
region and Taq polymerase cleaves the terminal nucleotide labeled with the 6-FAM ﬂuorophore via its 50-30 exonuclease activity releasing it from the
dual-quenched (ZEN and IBFQ) probe resulting in disruption of FRET and generation of a ﬂuorescence signal in response to excitation-induced
photon energy (hv). When the dNTP being measured (dTTP) is not present or becomes exhausted, Taq polymerase stalls, extension is inhibited/
terminated, ﬂuorescence remains quenched via FRET and the probe remains dark. In any given reaction, the level of ﬂuorescence generated is
directly proportional to the concentration of the limiting dNTP. The dAMP molecules enlarged in the template strand represent the nucleotides
opposite which the limiting dTTP nucleotides (also enlarged and in bold) will base pair. Only the nucleotide sequence found in the mid-template
dNTP detection region is given for simplicity. The complete sequences of all templates (including primer- and probe-binding regions), primer NDP1
and detection probes are given in Table 1. Template, primers and probes were prepared as described in ‘Materials and Methods’ section.
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NDP1) was designed complementary to the template 30
region and incorporated a GC clamp. NDP1 was also
designed to have a Tm of 56 C which is 5–10 C lower
than the Tm of the probes at 63–70 C. This facilitates
the speciﬁc binding order of the probe to the template,
followed by the primer to form a template:probe:primer
complex (TPP complex) and thus ensures that primer ex-
tension and template completion does not occur in the
absence of template-bound probe whereby no ﬂuorescence
would be generated. The sequences of all templates,
primers and probes are given in Table 1.
Polymerase selection
In contrast to previous template-based polymerase assays
that quantify dNTPs, the design of this assay necessitates
the use of a DNA polymerase with inherent 50 to 30 exo-
nuclease activity to cleave the ﬂuorophore-labeled probe
during successful polymerization and nascent strand syn-
thesis. In addition, one major drawback in previous
polymerase-based assays using Klenow polymerase was
the potential for misincorporation of rNTPs leading to
artiﬁcially elevated measurements particularly for dGTP
and dCTP (7). This was an important assay design con-
sideration as rNTPs can be present in cell extracts (quies-
cent cells in particular) in molar ratios 1000-fold greater
than their corresponding dNTP. Taq polymerase is
reported to be 30000-fold more efﬁcient at discriminating
beween ribo- and deoxyribonucleotides (300000-fold in
the case of dTTP and UTP) primarily due to a single
Glu-615 residue that can sterically exclude the 20-OH of
an incoming rNTP (19). A recent report identiﬁed Taq
polymerase as having a 10-fold higher capacity to discrim-
inate dNTPs from rNTPs than the commonly utilized
Klenow DNA polymerase and demonstrated no signiﬁ-
cant interference from rNTPs even at the extremes of
physiological rNTP concentrations (7). In addition to its
dNTP discriminatory capabilities, the utilization of
AmpliTaq Gold DNA polymerase that requires a
‘hot-start’ has a number of important advantages in this
assay. The inactivity of the enzyme before the hot-start
allows ﬂexibility in the reaction setup, including
pre-mixing of the reagents (including Taq polymerase
addition) at room temperature. This was conﬁrmed em-
pirically by performing plate setup on ice (3 C) versus
room temperature (22 C) with no signiﬁcant variation in
assay performance observed (data not shown). Second,
the hot-start also serves as an efﬁcient DNA denaturation
step after which the ramp down to 60 C facilitates the
sequential binding (based on calculated Tm) of the probe
followed by the primer to form the functional TPP
complex. In addition, Taq polymerase inactivity during
set-up and the ﬁrst temperature ramp of the assay
ensures that the timing of the reaction can be tightly
controlled for all individual reactions and replicates and
that mis-primed primers are not extended at temperatures
where sub-optimal primer annealing may occur. At the
60 C temperature in this assay and under optimum con-
ditions, Taq polymerase demonstrates  50% maximum
polymerization activity with 1U catalyzing the incorpor-
ation of 5nmol of dNTP into acid insoluble product in
30min at 60 C.
Validation of assay principle and performance
Initially, dTTP-DT6, -DT2 and -DT1 were all evaluated in
the assay for their ability to detect dTTP. The raw ﬂuor-
escence units obtained after 10-min incubation were
normalized to account for background probe ﬂuorescence
that was determined from controls lacking the limiting
dNTP. The resulting NFUs obtained from serial dilutions
of dTTP were utilized to generate calibration curves.
Consistent with the design hypothesis, dTTP-DT6 which
requires six dTTP incorporations per TPP complex to
yield ﬂuorescence demonstrated excellent linearity and
facilitated robust detection in the assayed range between
 10 and 100pmol of dTTP. dTTP-DT2 which requires
two dTTP incorporation events for extension also
demonstrated excellent linearity in the assayed range
Table 1. Primer, probe and templates utilized in the assay
Name Classiﬁcation Sequence (50–30) Size (bp) Tm ( C)
a
NDP-1 Primer CCGCCTCCACCGCC 14 56
FAM-dTTP Probe
b 6FAM/AGGACCGAG/ZEN/GCAAGAGCGAGCGA/IBFQ 23 70
dTTP-DT6 Template
c TCGCTCGCTCTTGCCTCGGTCCTTATTATTATTATTATTAGGCGGTGGAGGCGG 54 69
dTTP-DT2 Template
c TCGCTCGCTCTTGCCTCGGTCCTTTATTTATTTGGCGGTGGAGGCGG 47 72
dTTP-DT1 Template
c TCGCTCGCTCTTGCCTCGGTCCTTTATTTGGCGGTGGAGGCGG 43 73
FAM-dATP Probe
b 6FAM/TGGTCCGTG/ZEN/GCTTGTGCGTGCGT/IBFQ 23 68
dATP-DT2 Template
c ACGCACGCACAAGCCACGGACCAAATAAATAAAGGCGGTGGAGGCGG 47 73
dATP-DT1 Template
c ACGCACGCACAAGCCACGGACCAAATAAAGGCGGTGGAGGCGG 43 74
FAM-dCTP Probe
b 6FAM/AGGATTGAG/ZEN/GTAAGAGTGAGTGG/IBFQ 23 63
dCTP-DT2 Template
c CCACTCACTCTTACCTCAATCCTTTGTTTGTTTGGCGGTGGAGGCGG 47 70
dCTP-DT1 Template
c CCACTCACTCTTACCTCAATCCTTTGTTTGGCGGTGGAGGCGG 43 70
FAM-dGTP Probe
b 6FAM/ACCATTCAC/ZEN/CTCACACTCACTCC/IBFQ 23 64
dGTP-DT2 Template
c GGAGTGAGTGTGAGGTGAATGGTTTCTTTCTTTGGCGGTGGAGGCGG 47 71
dGTP-DT1 Template
c GGAGTGAGTGTGAGGTGAATGGTTTCTTTGGCGGTGGAGGCGG 43 71
aTm calculated in presence of 50mmol/l NaCl.
bLetters in bold and italics denotes the type and location of probe modiﬁcations.
cBases in bold and italics represent the dNTP to which the limiting dNTP will base pair opposite.
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which requires only a single dTTP incorporation event to
yield ﬂuorescence, demonstrated excellent linearity in the
assayed range between 0.6 and 10pmol ( 31–500nmol/l)
of dTTP. Calibration curves for all three dTTP DTs
demonstrated excellent linearity with R
2>0.99 in every
case (Figure 2). Subsequent analysis of the remaining
dNTPs (dATP, dCTP and dGTP) was performed using
their corresponding DT1 and DT2. DTs for all dNTPs
evaluated resulted in R
2>0.99 in every case and each
yielded similar detection ranges and NFU under the
same assay conditions (Figure 3).
Assay sensitivity, precision, accuracy and recovery
The mean LOD, which represents the smallest concentra-
tion or quantity of an analyte that can be reliably shown
to be present or measured under assay conditions was
investigated (20). The LOD was calculated from the
standard curve as the mean value of the negative control
plus 3 SD from three identical, inter-day assays and was
determined to be 0.46±0.02pmol for dTTP, 0.77±0.5
for dATP, 0.36±0.16 for dCTP and 0.38±0.1 for dGTP
(Table 2). The LOQ, deﬁned as the mean value of the
negative cosntrols plus 5 SD from three independent
assays, was determined by standard curve to be 0.88±
0.15pmol for dTTP, 1.3±0.1 for dATP, 0.77±0.2 for
dCTP and 0.81±0.01 for dGTP (Table 2).
The variability of the assay was evaluated by calculating
the inter- and intra-assay coefﬁcients of variation (%CV)
as described in the ‘Materials and Methods’ section. The
intra-assay coefﬁcients of variation (%CVs) were
determined to be 3.4±0.85 for dTTP, 3.64±1.2 for
dATP, 4.04±0.63 for dCTP and 4.58±0.77 for dGTP.
The interassay CV for dTTP was 8.5±6.3 for dTTP,
6.5±2.6 for dATP, 9.6±2.3 for dCTP and 4.1±3.5
for dGTP (Table 2).
Accuracy was determined in the low- and high- assay
range and was within 100±15% for all dNTPs (Table 2).
Recoveries were determined by obtaining the result from
an undetermined cell extract spiked with a known quantity
of a dNTP standard and comparing that to the sum of the
individual results obtained for the dNTP standard and the
extract determined separately. The assay method gave
high recoveries within 100±7% for all dNTPs (Table 2).
Assay optimization for the quantiﬁcation of intracellular
dNTPs
Progression of the polymerase reaction. Having demon-
strated the feasibility of a ﬂuorescence-based approach
to detect and quantify low picomole quantities of
dNTPs, the assay was optimized to determine the best
conditions for the detection and quantiﬁcation of
Figure 2. Validation of dTTP templates with varying detection
sensitivities and linear range. Three speciﬁc oligonucleotide templates
were initially generated and tested for their ability to detect dTTP and
tested by calibration curve as described in ‘Materials and Methods’
section. (A) dTTP-DT6 requires the incorporation of six dTTPs for
ﬂuorescence generation and yielded a linear range of 0–100pmol.
(B) dTTP-DT2 requires the incorporation of two dTTPs and yielded
Figure 2. Continued
a linear range of 0–25pmol. (C) Finally, dTTP-DT1 requires only a
single dTTP for incorporation per TPP complex to yield ﬂuorescence
and had a linear range of 0.6–10pmol. Calibration curves for all three
templates demonstrated R
2 of >0.993. In all cases, ﬂuorescence values
for blank reactions (limiting dNTP omitted) were subtracted to give
NFU.
PAGE 7 OF 15 Nucleic Acids Research, 2011,Vol.39, No. 17 e112Figure 3. Validation of dATP, dCTP and dGTP detection templates. Calibration curves were generated for dNTPs using dNTP-speciﬁc templates
(DT1 and DT2) and probes (Table 1) and were performed as described in ‘Materials and Methods’ section. In all cases, ﬂuorescence values for blank
reactions (limiting dNTP omitted) were subtracted to give NFU. All curves demonstrated R
2>0.99. (A) dATP, (B) dCTP, (C) dGTP. Left, DT1;
Right, DT2.
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Applied Biosystems 7500 Real-Time PCR System, the
real-time monitoring and ﬂuorescence data-capture over
speciﬁed 5-min time intervals was evaluated to monitor
the progress of the polymerase reaction to completion.
The generation of ﬂuorescence with DT1 was rapid and
robust with an incubation time of as little as 5min neces-
sary for the generation of calibration curves with good
signal:noise ratio and excellent linearity (R
2>0.99). All
subsequent time-points analyzed also showed excellent lin-
earity indicating that the polymerase reaction is progress-
ing in a linear manner and that substrate saturation has
not occurred and the polymerase is below Vmax. However,
while linear calibration curves could be generated for all
dNTPs with a 5min incubation period, the polymerase
reaction was not driven to completion (maximum DNA
synthesis) until approximately 15min for dGTP, dCTP
and dTTP and 20min for dATP (Figure 4). However,
for all dNTPs the NFUs obtained, and subsequent cali-
bration curves generated at the later time-points of 20 and
25min remained virtually identical to those obtained at
15min with R
2>0.99 in every case (Figure 4).
Considering the potential for the presence of inhibitory
molecules in cell extracts that may reduce assay kinetics,
these later time-points should facilitate the accurate quan-
tiﬁcation of dNTPs from cell extracts where the assay has
reached completion.
Evaluating assay interference from ribonucleotides. It has
been well established that DNA polymerases have imper-
fect dNTP selectivity both in vitro and in vivo (21,22).
Therefore one potential source of interference in the de-
tection of intracellular dNTPs is from endogenous rNTPs.
Although kinetic studies have revealed that Taq polymer-
ase in particular is reported to be highly efﬁcient at
discriminating between rNTP and dNTPs (7,19), the po-
tential for rNTP misincorporation resulting in overesti-
mation of dNTP recovery in the present assay was
tested. We measured the recovery of 5pmol of dNTP in
the presence and absence of 100- and 1000-fold molar
excess of the corresponding rNTP and followed the
assay in 5-min intervals to completion. A 100-fold molar
excess of rNTP did not result in any signiﬁcant increase in
the recovery of the corresponding dNTP. Similarly, a
1000-fold molar excess of rNTP did not induce any in-
creases in dNTP recovery (Figure 5). Interestingly, while
no evidence of signiﬁcant rNTP misincorporation was
evident, the presence of a 1000-fold molar excess of
rNTPs demonstrated a mild inhibitory effect on assay
kinetics. Speciﬁcally, the analysis of dGTP and dTTP
recovery at the earlier time-points of 5 and 10min
indicated the presence of a weak competitive effect of a
1000-fold rNTP molar excess and reduced assay kinetics
resulting in a reduced recovery of dGTP and dTTP
calculated at those time points. However, the effect was
transient and no evidence of rNTP-mediated assay inhib-
ition (or activation) was observed for any of the dNTPs at
the later time-points of 15 and 20min upon assay
completion.
Determination of intracellular dNTP pools. The current
assay was used to analyze the nucleotide pool content of
the human colon cancer cell line HCT116 in log-phase
growth and following treatment with anti-neoplastic ag-
ents known to perturb dTTP biosynthesis. The ﬂuoropyr-
imidines ﬂuorodeoxyuridine (FUdR) and 5-ﬂuorouracil
(5-FU) and the anti-folate pemetrexed are anti-neoplastic
chemotherapeutics that inhibits DNA synthesis through
inhibition of thymidylate synthase (TS), resulting in deple-
tion of dTMP an essential precursor to dTTP synthesis.
Cells were incubated with vehicle or 1mmol/l FUdR,
2.5mmol/l pemetrexed, or 5mmol/l 5-FU for 4h and pro-
cessed for analysis as described in ‘Materials and
Methods’ section. All dNTPs were successfully detected
and quantiﬁed from cell extracts during normal log-
phase growth (Table 3). Treatment with all three chemo-
therapeutics depleted dTTP pools as expected.
Speciﬁcally, 1mmol/l FUdR depleted dTTP >4-fold
from 20.4pmol in vehicle-treated cells to 4.5pmol per
10
6 cells while pemetrexed and 5-FU depleted dTTP
down to 3.9 and 1.6pmol per 10
6 cells, respectively. In
addition, while dATP showed no signiﬁcant change, de-
pletion of dGTP from 4.7 to 0.43, 1.1 and 0.9pmol per 10
6
cells following treatment with FUdR, pemetrexed and
5-FU, respectively was observed. Reductions in dCTP
levels from 10.5 to 8 and 8.7pmol per 10
6 was observed
following treatment with FUdR and 5-FU respectively
(Table 3).
Comparison to a validated LC–MS/MS assay for detecting
dNTPs. Our enzymatic assay for quantifying cellular
dNTPs was directly compared with results obtained
from a previously validated LC–MS/MS-based assay per-
formed by the Department of Clinical Pharmacy and
Pharmaceutical Sciences at the University of Southern
California (13). A known concentration of each dNTP
was provided from which calibration curves were
generated and the concentration of three biological
Table 2. Assay performance results for each dNTP determined from DT1
dNTP Regression
coefﬁcient
Accuracy
a Low,
High (%)
LOD (pmol) LOQ (pmol) Interassay
CV (%)
Intrassay
CV (%)
Recovery (%)
dTTP >0.995 114.9±6, 101.4±5.3 0.46±0.02 0.88±0.15 8.5±6.3 3.4±0.85 103.6
dGTP >0.998 98.9±11.7, 95.6±8.2 0.38±0.1 0.81±0.01 4.1±3.57 4.58±0.77 103.3
dATP >0.994 100.5±13.3, 101.6±7.7 0.77±0.5 1.3±0.1 6.5±2.6 3.64±1.2 93.2
dCTP >0.994 101.6±14.7, 100.3±5.26 0.36±0.16 0.77±0.2 9.6±2.3 4.04±0.63 96.4
aAccuracy was calculated in the low-mid and mid-high assay ranges.
LOD, limit of detection; LOQ, limit of quantiﬁcation.
PAGE 9 OF 15 Nucleic Acids Research, 2011,Vol.39, No. 17 e112Figure 4. Time-course and calibration curve analysis of the polymerase reaction. Time course showing ﬂuorescence generated by the
dNTP-dependent Taq DNA polymerase-mediated hydrolysis of a dual-quenched ﬂuorescent-labeled probe. Left. Known pmole quantities of
dNTP were detected using DT1 and ﬂuorescence was analyzed at 5-min intervals on board an Applied Biosystems 7500 Real-Time PCR System.
Right. Calibration curves were generated and plotted from the NFU obtained at the speciﬁed time intervals and analyzed by linear regression. All
calibration curves demonstrated R
2 of >0.99. (A) dGTP. (B) dTTP. (C) dATP. (D) dCTP. Additional details of the assay are described in the
‘Materials and Methods’ section.
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manner. The LC–MS/MS determination was performed
as described in the ‘Materials and Methods’ section. A
chromatograph illustrating the intensity measured in
counts per second (cps) and retention time for each dN
(dephosphorylated dNTPs) and internal standards is given
in Supplementary Figure S1B. The results obtained for
the unknowns by LC–MS/MS were directly compared
to those determined in the current ﬂuorescence-based
polymerase assay and the difference between the two
methodologies expressed as percent difference. Despite
the differing methodologies, reagents and instrumenta-
tion involved, the assay results were in good agreement
with mean±SD percent differences of  11±6% for
dCTP,  14±5.9% for dGTP,  5.2±11.6% for dTTP
and  4.5±13.4% observed for dATP between the two
assays.
Assay modiﬁcation to detect dUTP. The nucleotide inter-
mediate dUTP can be incorporated into newly synthesized
DNA opposite dAMP in place of dTTP, therefore an add-
itional application of this assay is the ability to measure
dUTP. In applications measuring dTTP pool imbalance
such as those that employ chemotherapeutics targeting
thymidylate metabolism, intracellular dUTP pools can ac-
cumulate in parallel with acute dTTP depletion and
provide inaccurate results in polymerase-based assays
(23–26). Therefore, in order to accurately determine the
concentrations of dTTP, the presence of any contributing
dUTP needs to be accounted for. The presence of dUTP
can be efﬁciently determined and accounted for by per-
forming parallel reactions with and without a
pre-incubation with the enzyme dUTPase which catalyzes
the hydrolysis of dUTP to dUMP and pyrophosphate and
removes its availability for nascent strand incorporation.
The dUTP pool concentration can thus be determined by
subtracting the results of cell extracts treated with
dUTPase from the untreated extracts. Importantly, the
AmpliTaq Gold polymerase buffer II was conducive for
Figure 5. Effect of a 100- and 1000-fold molar rNTP excess on the recovery of dNTPs in the ﬂuorescence-based assay with Taq polymerase. (A) The
recovery of 5pmol of dGTP was determined in the presence of both a 100- and 1000-fold molar excess of GTP at assay completion (20min). The
same analysis was applied to the recovery of (B) dATP, (C) dCTP and (D) dTTP in the presence of their corresponding rNTP. Bars represent the
mean+SD of three individual analyses. The assay was performed as described in ‘Materials and Methods’ section. In all cases, ﬂuorescence values
for blank reactions (limiting dNTP omitted) were subtracted to give NFUs.
Table 3. Intracellular dNTP concentrations determined from HCT116
human colorectal cancer cells treated with ﬂuoropyrimidine-based
thymidylate synthase inhibitors FUdR and 5-FU and the anti-folate
pemetrexed
dNTP pmol 10
6 cells
a
Control 1mmol/l
FUdR
2.5mmol/l
PTX
5mmol/l
5-FU
dATP 13.6±1.17 14.5±0.13 13.4±1.68 13.9±0.33
dCTP 10.5±0.2 8±0.04 11.1±2.5 8.7±0.24
dGTP 4.7±0.8 0.43±0.11 1.14±0.3 0.88±0.1
dTTP 20.4±0.77 4.5±0.71 3.93±0.8 1.64±0.16
aValues represent the mean±SD determined from two independent
isolations analyzed in duplicate. Cells were treated for 4h with
vehicle (sterile ddH20 or DMSO) or with the speciﬁed concentrations
of PTX; pemetrexed, FUdR; ﬂuorodeoxyuridine, 5-FU; 5-ﬂuorouracil.
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drolysis of 25pmol of dUTP was observed with a 10min
incubation with 5ng of dUTPase at 37 C prior to initi-
ation of the normal assay program. The inclusion of
dUTPase in the assay reaction mix did not interfere with
assay performance as evidenced by parallel reactions
measuring dTTP with and without dUTPase that
demonstrated excellent linearity (R
2>0.99) and were vir-
tually identical (Figure 6A). When dUTP was measured as
the rate-limiting dNTP, excellent linearity was also
recorded, however, partial digestion resulting in inter-
mediate ﬂuorescence was observed with 2.5ng of
dUTPase. Increasing the amount of enzyme to 5ng of
dUTPase per reaction completely hydrolyzed 25pmol
yielding no ﬂuorescence signal above background
(Figure 6B). This conﬁrmed the speciﬁcity of the assay
for the limiting dNTP (dUTP in this instance) and con-
ﬁrmed that the assay has the potential to be modiﬁed to
accurately measure dUTP in addition to the canonical
dNTPs.
DISCUSSION
The development of ﬂuorescence-based assays is continu-
ing to improve the sensitivity, speciﬁcity and throughput
of an increasing number of assays for the measurement of
biological molecules and for bioimaging molecular
processes. The current assay is a novel ﬂuorescence-based
approach utilizing ﬂuorescence technology to provide a
rapid, sensitive and cost-effective alternative to current
methodologies that necessitate the incorporation of radio-
activity and/or HPLC and MS instrumentation for the
detection of dNTPs. This assay was successfully applied
to the detection of dATP, dTTP, dGTP, dCTP and dUTP
in in vitro assays and in the quantiﬁcation of intracellular
dNTP pools from human cancer cells.
The current assay was validated in line with current
FDA guidelines for analytical assays and demonstrated
excellent accuracy, sensitivity, reproducibility and recovery
within accepted guidelines. The current assay has several
inherent qualities that make it more attractive and efﬁcient
than radiolabeling or HPLC and LC–MS/MS methods
that are still currently in use. One limitation with conven-
tional template-based DNA polymerase assays is the lim-
ited linear range up to 10pmol. To address this, we have
designed and validated additional detection templates that
allow detection of up to 60pmol of dNTP at assay com-
pletion thereby signiﬁcantly expanding the linear detection
range. For example, in assays were maximum sensitivity is
required such as dNTP detection from low numbers of
prokaryotic and eukaryotic cells, DT1 which requires
only a single limiting dNTP incorporation event for ﬂuor-
escence generation, would provide the most sensitive de-
tection of low picomole quantities of dNTP. However, if
an in vitro enzymatic screening assay is being performed
and extreme sensitivity is not required, DT6 which
requires six limiting dNTP incorporation events to yield
ﬂuorescence, would provide a broader range of linear de-
tection ( 5–60pmol at assay completion) and may be
more suitable. It should be noted that while the LOD of
the current assay ranges from 0.3 to 0.7pmol depending
on the dNTP, current radiolabeling methods report the
ability to accurately measure dNTP quantities down to
0.1pmol (7). However, the current assay has sufﬁcient
sensitivity for the majority of cell-based applications
without the requirement for excessive or impractical cell
numbers. Previous analyses of human intracellular dNTP
concentrations report ranges of 2–80pmol of dNTP per
10e
6 (3,4,9,27,28), with microbiological applications
Figure 6. Detection of dUTP. The ability of the assay to detect dUTP
and distinguish dTTP from dUTP in the presence and absence of the
dUTP-hydrolyzing enzyme dUTPase was analyzed. (A) The effects of
including recombinant human dUTPase (DUT) and a 5min
pre-incubation at 37 C were ﬁrst analyzed. Inclusion of 5ng of
dUTPase had no signiﬁcant impact on the assay performance and de-
tection of dTTP (R
2>0.99). (B) dTTP was replaced with dUTP and the
reaction performed in the absence of dUTPase and in the presence of
2.5 and 5ng of recombinant human dUTPase. In the absence of
dUTPase, dUTP detection was robust and yielded an excellent calibra-
tion curve (R
2>0.99). Five nanograms of dUTPase was sufﬁcient to
eliminate dUTP as the source of ﬂuorescence in the assay, whereas
2.5ng resulted in partial hydrolysis and intermediate ﬂuorescence.
The assay was performed as described in ‘Materials and Methods’
section. In all cases, ﬂuorescence values for blank reactions (limiting
dNTP omitted) were subtracted to give NFUs.
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7 cells
[Saccharomyces cerevisiae (29)]. However, the analysis
of dNTP pools in cells not undergoing DNA replication,
or the quantiﬁcation of mitochondrial dNTP pools may
represent a challenge for the current assay as these values
may approach and exceed the limit of detection from
an initial sample size of 10
6 cells. Such analyses would
thus require a larger initial sample size to facilitate
accurate quantiﬁcation (30). It is also plausible that dif-
ferent probe designs and/or combinations of reporter
and quencher molecules in the probe may facilitate an
increase in sensitivity in the assay and this is currently
being explored. Although the ﬂuorophore detection
capabilities of real-time PCR platforms vary, numer-
ous commercially available ﬂuorophore and quencher
combinations are available to suit the requirements of
most platforms and applications (14) and could be
adapted to the FRET technology that this assay is based
upon.
One additional advantage of the current assay over
the conventional radiolabeled dNTP polymerase assays
is that there is no interference in the current assay from
the endogenous cellular dNTP corresponding to the radio-
labeled dNTP substrate ([3H]dNTP) as previously
reported (4). An additional issue with the radiolabeled
assay is that the speciﬁc radioactivity of dNTPs in radio-
isotope experiments cannot be measured. The current
assay circumvents this issue by avoiding the need for a
radiolabeled dNTP and employing a ﬂuorescence-labeled
probe that demonstrates robust linearity. One key attri-
bute of the current assay is the straightforward and un-
complicated assay set up. All reagents can be added and
mixed at room temperature and the use of a
96-well-format real-time PCR instrument facilitates the
simultaneous analysis of all dNTPs with the ability
monitor assay kinetics in real-time by acquiring ﬂuores-
cence readings at multiple user-deﬁned time-points to
follow progression of the polymerase reaction and
ensure analysis occurs at the most appropriate interval
without the need to irreversibly terminate the polymerase
reaction and extract the sample for downstream detection.
In addition, recent optimization of the radiolabeled DNA
polymerase assay identiﬁed the potential for rNTP
misincorporation for dCTP and dGTP and recommended
that either Taq or Sequenase DNA polymerase be used for
accurate analysis of dCTP and dGTP whereas analysis of
dTTP and dATP could be performed with Klenow DNA
polymerase. The current assay provides the ability to
measure all four canonical cellular dNTPs on a single
96-well plate under identical assay detection conditions
with the same DNA polymerase. In addition, consistent
with previous observations, the use of Taq polymerase in
this assay also appears to signiﬁcantly limit the potential
for dNTP overestimation as a result of rNTP
misincorporation (7).
The requirement for specialized equipment is limited to
a 96-well ﬂuorescence plate reader or preferably a
real-time PCR thermocycler, neither of which require a
high degree of specialized training and are signiﬁcantly
less costly to purchase, operate and maintain than
HPLC and LC–MS/MS-based instrumentation. In
addition, the current assay is extremely rapid with the
ﬁnal detection step requiring  30min. If extraction of
intracellular nucleotides is required, the entire protocol
can be completed in <3h including extraction and con-
centration of dNTPs, plate setup and ﬁnal detection. The
small reaction volume, low enzyme and probe requirement
per reaction also make this a relatively inexpensive assay.
The current assay was also directly compared to a
validated LC–MS/MS-based approach for detecting and
quantifying dNTPs and despite the distinct contrast in
techniques, the results obtained for unknown samples
were in good agreement.
The assay was also modiﬁed to measure the nucleotide
intermediate dUTP (which can be utilized as a substrate
by DNA polymerase) with excellent results. By per-
forming the reaction with dUTP in the presence and
absence of the dUTP-hydrolyzing enzyme dUTPase,
both the ﬂexibility of the assay and the substrate speciﬁ-
city was conﬁrmed. As expected, a short pre-incubation
with sufﬁcient dUTPase completely eliminated ﬂuores-
cence compared to the no-enzyme control for dUTP but
not dTTP conﬁrming the speciﬁcity of the limiting dNTP
(dUTP) as the source of ﬂuorescence generation in the
assay.
The determination of intracellular dNTP levels is of
fundamental importance in understanding the under-
lying biology of a number of genetic diseases and in
determining the mechanisms of action of a wide range
of pharmacological agents designed to perturb dNTP me-
tabolism and DNA replication in both prokaryotic and
eukaryotic organisms. This assay therefore has import-
ant and broad application in research measuring dNTPs
and/or the activity and inhibition of enzymes directly
or indirectly involved in dNTP biosynthesis. The
accurate quantiﬁcation of dNTP pools in response to
anti-cancer agents that target dNTP biosynthesis repre-
sents one important application and was the primary
motivating factor that led to the development of this
assay. We conﬁrmed this application by successfully
measuring perturbations in dTTP pools in human tumor
cells as a result of inhibiting a key enzyme involved in
dTTP biosynthesis. Treatment with FUdR, 5-FU and
pemetrexed resulted in rapid perturbations in dNTP
pools similar to those previously reported for both these
agents. Speciﬁcally, measurable decreases in both dTTP
and dGTP concentrations were observed (31–33). The
intracellular dNTP concentrations obtained for tumor
cells with the current assay were within 15–20% of previ-
ously published studies using similar models and condi-
tions (3,10,11,25,34).
One critical attribute of this assay is its potential for
adaptation to high-throughput applications (384-well
and beyond), making it particularly amenable to high
sample volumes or to the screening of pharmacological
molecules that perturb dNTP metabolism either from
cell-based assays or in vitro screening.
In summary, the ﬂuorescence-based dNTP detection
assay described in this manuscript represents a rapid, sen-
sitive, reproducible and cost-effective alternative to
current radiolabeling and HPLC and MS-based method-
ology to detect and quantify dNTPs.
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Since online publication of their article, the authors
have made some modiﬁcations to the method described
in their article resulting in signiﬁcantly improved
performance. The new method supersedes the one
described in the main text of the article. The new
method has been uploaded as a Supplementary File
and contains three new ﬁgures. The new method does
not inﬂuence the validity of the results and conclusions
of the article.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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